Hypophosphatasia (HPP) is the metabolic bone disease caused by loss-of-function mutation within the gene that encodes the "tissue nonspecific" isoenzyme of alkaline phosphatase (TNSALP). Perinatal HPP is usually fatal due to respiratory insufficiency, and infantile HPP often has a similar outcome although no formal study into the natural history of these severe forms of HPP has been undertaken. We reviewed our 80-year (1927-2007) cohort of 15 Canadian patients with perinatal HPP. All had Mennonite heritage. Family linkage studies indicated that nine were homozygous for a TNSALP disease allele, likely Gly334Asp. Three patients had parents who were carriers for the Gly334Asp allele by mutation analysis. One patient was confirmed by mutation analysis to be homozygous for the TNSALP Gly334Asp mutation. One patient who had only one Mennonite parent was a genetic compound for the Gly334Asp mutation and the Val382Ile mutation. This patient's sibling was also affected. All 15 patients had profound skeletal hypomineralization, severe rickets, and respiratory insufficiency. All died by 9 months of age, usually soon after birth, from pulmonary failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755555 | PMC |
| http://dx.doi.org/10.1007/8904_2013_224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pain, quality of life, and integral management in a cohort of patients diagnosed with hypophosphatasia in Colombia.
Orphanet J Rare Dis
November 2024
NeuroEconomix, Bogotá D.C., Colombia.
Article Synopsis
- - This study investigates pain, quality of life, and healthcare access for Colombian patients with hypophosphatasia (HPP), a genetic disease that varies greatly in severity.
- - Using three specific questionnaires, the research analyzed 18 HPP patients, revealing that issues related to overall health, vitality, and pain were prominent among participants.
- - Findings indicated that patients generally experienced mild to moderate pain and impairment in their quality of life, impacting daily activities, but with notable variability in individual responses.
Rare diseases: a challenge in paediatric dentistry.
Eur J Paediatr Dent
September 2024
Director of the Postgraduate School of Paediatric Dentistry, University of Pisa.
Article Synopsis
- - Rare diseases, though infrequent (happening in 100-500 per million), pose significant challenges in pediatric dentistry due to their complex needs and the required specialized care.
- - Conditions like X-linked hypophosphatemic rickets (XLH), hypophosphatasia (HPP), and osteogenesis imperfecta (OI) show how systemic health problems can directly affect oral health, necessitating a multidisciplinary approach for effective treatment.
- - XLH is particularly notable, caused by mutations in the PHEX gene, leading to issues such as poor enamel mineralization, dental abscesses, and unique dental manifestations, emphasizing the crucial role dentists play in early diagnosis and referrals to genetic specialists.
Challenges in Hypophosphatasia: Suspicion, Diagnosis, Genetics, Management, and Follow-Up.
Horm Res Paediatr
August 2024
Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Background: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function variants in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (ALP) activity. This results in a distinctive biochemical profile marked by low serum ALP levels and elevated pyridoxal-5-phosphate (PLP). The clinical spectrum of HPP ranges from perinatal lethality to asymptomatic cases, presenting significant diagnostic and therapeutic challenges.
View Article and Find Full Text PDFEnzyme replacement therapy for hypophosphatasia-The current paradigm.
Clin Endocrinol (Oxf)
December 2024
Child Health Research Centre and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Hypophosphatasia (HPP) is a rare, inherited, and systemic disorder characterized by impaired skeletal mineralization and low tissue nonspecific serum alkaline phosphatase (TNSALP) activity. It is caused by either autosomal recessive or dominant-negative mutations in the gene that encodes TNSALP. The phenotype of HPP is very broad including abnormal bone mineralization, disturbances of calcium and phosphate metabolism, pain, recurrent fracture, short stature, respiratory impairment, developmental delay, tooth loss, seizures, and premature death.
View Article and Find Full Text PDFPediatric hypophosphatasia: avoid diagnosis missteps!
J Bone Miner Res
July 2024
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis; St. Louis, MO 63110, United States.
Article Synopsis
- Hypophosphatasia (HPP) is a genetic disorder that affects bones and teeth because a specific gene called ALPL doesn’t work right.
- When ALPL is mutated, it leads to a buildup of substances that can weaken bones and teeth, causing issues like weak muscles.
- Diagnosing HPP can be tricky because it has different forms and symptoms, but testing the ALPL gene and using special treatments can help manage it better.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!